AstraZeneca cancels marketing rights for Muse
This article was originally published in Clinica
Executive Summary
AstraZeneca has terminated its agreement with VIVUS for Muse, the US company's erectile dysfunction treatment and has returned the marketing and distribution rights to VIVUS. The move will be a further setback for VIVUS, which has seen demand for its product plummet following the success of Pfizer's impotence pill, Viagra, which was launched last year.